Understanding Controller vs. Reliever Therapies in Asthma

In asthma management, medications are broadly classified into two categories: reliever (rescue) therapies, which provide quick relief of acute bronchospasm, and controller (maintenance) therapies, which are taken regularly to reduce airway inflammation, control chronic symptoms, and prevent exacerbations. The question asks which of the listed drugs fall into the controller category.

Analysis of Each Option

• 1. Anticholinergics: Short-acting anticholinergics such as ipratropium bromide are bronchodilators used for quick relief during acute exacerbations, typically in combination with short-acting beta-agonists (SABAs). They act by blocking bronchoconstriction rather than treating underlying airway inflammation, so they are classified as reliever, not controller, therapy. (Long-acting anticholinergics like tiotropium are used as add-on controllers in select severe asthma cases, but plain "anticholinergics" in this context refers to the reliever role.) This statement is incorrect for controller therapy.
• 2. Systemic Glucocorticoids: Oral or intravenous corticosteroids (e.g., prednisolone, methylprednisolone) are used as controller therapy in moderate-to-severe persistent asthma and during exacerbations to suppress airway inflammation over a sustained period. This is correct.
• 3. Inhaled Glucocorticoids: Inhaled corticosteroids (ICS) such as budesonide and fluticasone are the cornerstone controller medications in asthma. They are taken daily to reduce airway inflammation and prevent exacerbations, forming the basis of stepwise asthma therapy at essentially every GINA step. This is correct.
• 4. Omalizumab: This anti-IgE monoclonal antibody is a controller/add-on biologic therapy used in severe allergic asthma poorly controlled on standard ICS-based regimens. It works to reduce the frequency of exacerbations over time. This is correct.

Conclusion

Controller therapies work through sustained anti-inflammatory or immunomodulatory action to prevent asthma symptoms and exacerbations. Of the options listed, Systemic glucocorticoids, Inhaled glucocorticoids, and Omalizumab (2, 3, and 4) fit this definition, while Anticholinergics function as quick-relief bronchodilators rather than controllers.

Therefore, the correct answer is 2, 3 and 4.